Announcement • Aug 13
Eevia Health Plc Announces Resignation of Terry Virts as Chairman ,Effective on May 28, 2025 Eevia Health Plc informed that Terry Virts resigned as Chairman for personal reasons on May 28, with the resignation registered with the Finnish Patent and Registration Office (PRH) on July 2. The timely public announcement of the change was overlooked due to the non-execution of a called Extraordinary General meeting on May 30. Furthermore, the Board currently has four members, but due to an earlier administrative event (reported earlier), only three are formally registered with the PRH. These registration issues will be corrected shortly. A new Chairman will be elected and registered at the next General Meeting, together with any other elections. On May 28, Terry Virts informed the Board of his resignation to pursue a political career in his home country. His departure was intended to be addressed at a planned Extraordinary General Meeting (EGM) scheduled for May 30, where a new Chairman would be elected. However, due to sick leave among key participants and the absence of shareholders at the meeting, the EGM was never legally convened. This "no-show" was not promptly reported to the public and caused that the vacancy was not filled. When the AGM was also delayed, the issue was prolonged over the summer, while the various issues were also not properly reported to the public due to capacity issues in the Administration. The resignation was later registered with the Finnish Patent and Registration Office (PRH) on July 2, but a clerical error incorrectly listed Per Benjaminsen as Chairman, which is being corrected with PRH. Furthermore, in January 2025, the Board appointed Marinus Sørensen to fill a vacancy, believing this to be permissible under the Finnish Limited Liability Companies Act. However, questions were later raised about whether such appointments can only be made by a General Meeting as stipulated by the Finnish Companies Act. As reported earlier, the Board consider that the state in the Limited Liability Companies Act dominates the Company Act, but due to a miscommunication with the person undertaking PRH registration back in February, Mr. Sørensen's appointment was never formally registered with the Finnish Patent and Registration Office, despite being announced publicly. This issue was also supposed to be handled through elections in the planned EGM, or secondarily in the AGM. However, since both meetings are not yet held, only three of the Board's four current members are formally registered with PRH. Eevia are resolving these issues by updating registrations with the authorities and ensuring that the upcoming General Meeting elects a chairman and the required number of Board members. The current Board remains operational, is self-organizing and will appoint an Interim Chairman from among its members to lead proceedings until the General Meeting. Announcement • Jul 23
Eevia Health Oyj to Report Q2, 2025 Results on Aug 21, 2025 Eevia Health Oyj announced that they will report Q2, 2025 results on Aug 21, 2025 Announcement • Jun 13
Eevia Health Relocates Production to Norwegian Nutraceutical Biotechnology Hub to Drive Innovation, Avoid Investments and Cut Costs Eevia Health Plc is implementing a strategic reorganization that includes closing its manufacturing facility in Finland, and relocating operations to BIOTEP, a state of the art biotechnology processing facility in Tromsø, Norway, operated by the Norwegian research institute Nofima. This move will provide Eevia with access to advanced technologies without the need for capital investment and is expected to reduce fixed costs by 60% through a flexible, pay-per-use "rent-a-factory" model. More importantly, the new location offers direct access to cutting-edge R&D infrastructure and expert personnel, supporting both process optimization and product innovation. To meet these challenges and strengthen the foundation for future growth, the Board of Eevia has decided to close Eevia's manufacturing site in Finland and move the production and process development to BIOTEP in Tromsø, Norway, an advanced and flexible facility operated by the Norwegian food research institute Nofima. Eevia will rent the production facility including BIOTEP personnel on an "as needed" basis allowing for a significant reduction in running foxed costs. During rented production timeslots, Eevia retains full control over its production processes, mitigating operational risk, while enjoying the use of advanced technologies and avoiding the required investments in own facility. This transition will impact up to eight employees in Finland. Eevia will work closely with affected staff to ensure a responsible and respectful transition. Eevia will retain its core functions in sales, IP ownership, R&D, and global market development. 
